George Yancopoulos - Regeneron Pharmaceuticals President

REGN -- USA Stock  

USD 288.12  2.23  0.78%

  President
Dr. George D. Yancopoulos, M.D., Ph.D., is President and Chief Scientific Officer Regeneron, Director of the Company. Dr. Yancopoulos joined Dr. Schleifer in 1989 as founding scientist of the Company, and together they built and have managed the Company since then. Dr. Yancopoulos is currently President and Chief Scientific Officer, and has served on the board since 2001. He received his M.D. and Ph.D. from Columbia University. Dr. Yancopoulos was the 11th most highly cited scientist in the world in the 1990s, and in 2004 he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos, together with key members of his team, is a principal inventor andor developer of the five FDAapproved drugs the Company has developed, EYLEA Injection, Praluent Injection, Dupixent Injection, ZALTRAP Injection for Intravenous Infusion, and ARCALYST Injection for Subcutaneous Use, as well as of its foundation technologies, including the TRAP technology, VelociGene, and VelocImmune. As one of the few members of the National Academy of Sciences from industry and as an author of a substantial number of scientific publications, Dr. Yancopoulos has a distinguished record of scientific expertise
Age: 58  President Since 2016      
914-847-7000  http://www.regeneron.com
Yancopoulos also brings to the board his experience in building and managing the Company, his indepth knowledge of the Company?s technologies and research and development programs, and his proven trackrecord for envisioning successful longterm strategic directions and opportunities.

George Yancopoulos Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 11.57 % which means that it generated profit of $11.57 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 24.43 % meaning that it created $24.43 on every $100 dollars invested by stockholders.
The company currently holds 711.3M in liabilities with Debt to Equity (D/E) ratio of 7.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals has Current Ratio of 3.8 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Alejandro BernalZoetis
2015
J RamachandranDr Reddys Laboratories Ltd
2016
Sripada ChandrasekharDr Reddys Laboratories Ltd
2013
Alok SonigDr Reddys Laboratories Ltd
2015
Jeffrey NeedhamPerrigo Company plc
2009
Jatin ShahPerrigo Company plc
2005
Roxanne LaganoZoetis
2015
Roman TrawickiZoetis
2015
Jeffrey ChodakewitzVertex Pharmaceuticals Incorpor
2014
Ganadhish KamatDr Reddys Laboratories Ltd
2016
Saumen ChakrabortyDr Reddys Laboratories Ltd
2018
John WesolowskiPerrigo Company plc
2016
Catherine KnuppZoetis
2012
Heidi ChenZoetis
2012
Joyce LeeZoetis
2012
Glenn DavidZoetis
2016
Amit BiswasDr Reddys Laboratories Ltd
2016
James MichaudPerrigo Company plc
2016
Paul WeningerPerrigo Company plc
2015
Charles MilsteinVertex Pharmaceuticals Incorpor
2017
Reshma KewalramaniVertex Pharmaceuticals Incorpor
2018

Entity Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 7549 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 7,549 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent Director
Joseph Goldstein, Independent Director
Anthony Coles, Independent Director
George Sing, Independent Director
Peter Powchik, Senior Vice President - Clinical Development
Jay Markowitz, Senior Vice President - Portfolio Management
Robert Terifay, Sr. VP of Commercial
Robert Landry, CFO and Sr. VP of Fin.
Michael Brown, Independent Director
Christine Poon, Independent Director
Neil Stahl, Executive VP of RandD
Marion McCourt, Senior Vice President and Head of Commercial
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director
Huda Zoghbi, Director
Bonnie Bassler, Director
Joseph LaRosa, Senior Vice President General Counsel, Secretary
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply
Leonard Schleifer, President CEO, Director
Alfred Gilman, Independent Director
Roy Vagelos, Chairman of the Board
Michael Aberman, Vice President - Strategy
Manisha Narasimhan, IR Contact
Douglas McCorkle, Vice President Controller, Assistant Treasurer
Marc TessierLavigne, Independent Director
Christopher Fenimore, Vice President Controller
Arthur Ryan, Independent Director

Stock Performance Indicators

Did you try this?

Run Content Syndication Now

   

Content Syndication

Quickly integrate customizable finance content to your own investment portal
All  Next Launch Module

Currently Active Assets on Macroaxis

HCP   
Purchased over 300 shares of
few hours ago
Traded for 35.11
PAGS   
Sold over 200 shares of
few hours ago
Traded for 47.76
AVP   
Purchased over 100 shares of
few hours ago
Traded for 4.78
MOH   
Purchased over 100 shares of
few hours ago
Traded for 115.25
TTD   
Purchased over 50 shares of
few hours ago
Traded for 213.25
Additionally take a look at Your Equity Center. Please also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of macroaxis ideas.
Search macroaxis.com